The Changing Face of Newly Diagnosed AML: Is There a Role for IDH Inhibitors?
To continue, select another chapter from the Chapter List
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, Dr. Pollyea will outline the clinical imperative for mutational testing for IDH mutations during prognosis of AML and the implications of IDH1 and IDH2 mutations on prognosis and treatment selection. He will share the latest data which compare and contrast trial endpoints of elimination of minimal residual disease versus mutational clearance and relate each to its clinical impact in newly diagnosed AML patients. In addition, Dr. Pollyea will report on promising clinical trials of IDH1 and IDH2 inhibitors for AML, both alone and in combination with other therapies in the frontline setting.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Outline the clinical imperative for mutational testing for IDH mutations during diagnosis of AML and the implications of IDH1 and IDH2 mutations on prognosis
- Compare and contrast trial endpoints of elimination of minimal residual disease (MRD) versus mutation clearance, and relate each to its clinical impact in newly diagnosed AML patients
- Describe promising clinical trials of IDH1/2 inhibitors for AML, both alone and in combination with other therapies, in the frontline setting
- Identify newly diagnosed AML patients who are candidates for clinical trials of IDH1/2 inhibitors
The Changing Face of Newly Diagnosed AML: Is There a Role for IDH Inhibitors? – Daniel A. Pollyea, MD
Instructions for Participation and Credit
This activity is eligible for credit through April 30, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Daniel A. Pollyea, MD
Clinical Director of Leukemia Services
Associate Professor of Medicine
Division of Hematology
University of Colorado
Dr. Daniel Pollyea completed his medical training at the University of Chicago Pritzker School of Medicine and his residency training in internal medicine at the University of Chicago Hospitals. He served as Chief Medical Resident at Chicago’s Cook County Hospital and then went to Stanford University for his fellowship training in hematology and oncology, where he also earned a master’s degree in epidemiology. He is now an Associate Professor of Medicine at the University of Colorado in the Division of Hematology, where he also serves as the Clinical Director of Leukemia Services.
Dr. Pollyea’s research interests involve understanding the nature of leukemia stem cells, and finding ways to target them in clinical trials with novel therapies. He serves as principal investigator of multiple clinical trials, has received grant funding from the Leukemia and Lymphoma Society, and has published more than 60 peer-reviewed journal articles.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Helsinn.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-017-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Daniel Pollyea has received honoraria as a consultant from AbbVie Inc, Amgen Inc., Celgene Corporation, Daiichi Sankyo, Inc., Forty Seven Inc., Janssen Pharmaceuticals, Inc., and Takeda Oncology. He has received grant support related to research activities from AbbVie and Pfizer Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.